Cargando…
Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib
Brain metastases are a common complication of non-small-cell lung cancer (NSCLC). The role of chemotherapy in the treatment of brain metastases has not been clearly defined. Emerging case reports of patients with recurrent NSCLC treated as part of the Expanded Access Programme reveal that gefitinib...
Autores principales: | Katz, A, Zalewski, P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750244/ https://www.ncbi.nlm.nih.gov/pubmed/14661048 http://dx.doi.org/10.1038/sj.bjc.6601478 |
Ejemplares similares
-
High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
por: Zhang, Ying, et al.
Publicado: (2021) -
siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells
por: Yuan, Heng-Heng, et al.
Publicado: (2017) -
Pharmacology and antitumour effects of intraportal pirarubicin on experimental liver metastases.
por: Ramirez, L. H., et al.
Publicado: (1993) -
Antitumour activity of peroxidases.
por: Everse, K. E., et al.
Publicado: (1985) -
The antitumour activities of statins
por: Takahashi, H.K., et al.
Publicado: (2007)